Literature DB >> 34978157

Optimal duration of adjuvant bisphosphonate treatment for high-risk early breast cancer: Results from a SUCCESS trial.

Mingbei Lu1, Beibei Ren1, Lingyan Rao1.   

Abstract

Entities:  

Keywords:  SUCCESS A trial; adjuvant bisphosphonate treatment; breast cancer; treatment duration

Mesh：

Substances：

Year:  2022        PMID： 34978157      PMCID： PMC8807267          DOI： 10.1111/1759-7714.14257

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN： 1759-7706            Impact factor:   3.500


× No keyword cloud information.
  15 in total

1.  Bone health in cancer: ESMO Clinical Practice Guidelines.

Authors:  R Coleman; P Hadji; J-J Body; D Santini; E Chow; E Terpos; S Oudard; Ø Bruland; P Flamen; A Kurth; C Van Poznak; M Aapro; K Jordan
Journal:  Ann Oncol       Date:  2020-08-12       Impact factor: 32.976

2.  Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Authors:  Elisabeth Trapp; Wolfgang Janni; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Amelie de Gregorio; Marianna Alunni-Fabbroni; Marie Tzschaschel; Arkadius Polasik; Julian G Koch; Thomas W P Friedl; Peter A Fasching; Lothar Haeberle; Tanja Fehm; Andreas Schneeweiss; Matthias W Beckmann; Klaus Pantel; Volkmar Mueller; Brigitte Rack; Christoph Scholz
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

3.  Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.

Authors:  M Clemons; K A Gelmon; K I Pritchard; A H G Paterson
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

4.  Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Joseph Sparano; Anne O'Neill; Katherine Alpaugh; Antonio C Wolff; Donald W Northfelt; Chau T Dang; George W Sledge; Kathy D Miller
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Authors:  M Gnant; B Mlineritsch; H Stoeger; G Luschin-Ebengreuth; M Knauer; M Moik; R Jakesz; M Seifert; S Taucher; V Bjelic-Radisic; M Balic; H Eidtmann; W Eiermann; G Steger; W Kwasny; P Dubsky; U Selim; F Fitzal; G Hochreiner; V Wette; P Sevelda; F Ploner; R Bartsch; C Fesl; R Greil
Journal:  Ann Oncol       Date:  2014-11-17       Impact factor: 32.976

7.  Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.

Authors:  Hsien Liu; Shih-Han Wang; Shin-Cheh Chen; Ching-Ying Chen; Tsun-Mei Lin
Journal:  BMC Cancer       Date:  2019-02-26       Impact factor: 4.430

8.  Cancer burden of major cancers in China: A need for sustainable actions.

Authors:  Maomao Cao; He Li; Dianqin Sun; Wanqing Chen
Journal:  Cancer Commun (Lond)       Date:  2020-05-02

9.  Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.

Authors:  Thomas W P Friedl; Tanja Fehm; Volkmar Müller; Werner Lichtenegger; Jens Blohmer; Ralf Lorenz; Helmut Forstbauer; Visnja Fink; Inga Bekes; Jens Huober; Julia Jückstock; Andreas Schneeweiss; Hans Tesch; Sven Mahner; Sara Y Brucker; Georg Heinrich; Lothar Häberle; Peter A Fasching; Matthias W Beckmann; Robert E Coleman; Wolfgang Janni; Brigitte Rack
Journal:  JAMA Oncol       Date:  2021-08-01       Impact factor: 33.006
View more
  1 in total

Review 1.  Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs.

Authors:  Emanuela Chiarella; Clelia Nisticò; Anna Di Vito; Helen Linda Morrone; Maria Mesuraca
Journal:  Biomedicines       Date:  2022-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.